Familial hypercholesterolaemia patient support groups and advocacy: A multinational perspective

Area of Science:

• Cardiovascular Medicine
• Genetics and Heredity
• Public Health

Background:

• Familial hypercholesterolaemia (FH) is an autosomal-dominant genetic disorder.
• It causes significantly elevated low-density lipoprotein cholesterol (LDL-C) levels.
• Untreated FH leads to premature cardiovascular disease, with 50% of men and 30% of women developing coronary heart disease by ages 50 and 60, respectively.

Purpose of the Study:

• To explore the development and essential components of effective advocacy within Familial hypercholesterolaemia patient organizations.
• To highlight the critical role of medical and scientific expertise in strengthening FH patient advocacy.
• To examine successful advocacy models from various international patient organizations.

Main Methods:

• Review of case studies from FH patient organizations in Canada, the Netherlands, Spain, the US, and the UK.
• Analysis of the structure and impact of the pan-European patient organization, FH Europe.
• Qualitative assessment of the integration of medical and scientific input into advocacy strategies.

Main Results:

• FH patient advocacy benefits significantly from a strong connection with medical and scientific communities.
• Credible and well-founded advocacy is achieved through this collaboration.
• Patient associations need a long-term perspective to drive improvements in FH identification and treatment.

Conclusions:

• Effective advocacy for Familial hypercholesterolaemia necessitates a robust partnership between patient organizations and the medical-scientific community.
• Sustained, long-term strategies are crucial for improving the diagnosis and management of FH globally.
• International collaboration and shared expertise enhance the credibility and impact of patient advocacy efforts.